Oct15Mon
Oct11Thu
Spark Therapeutics to add up to 500 jobs in West Philadelphia expansion
Spark Therapeutics Inc. said Thursday it is expanding its research-and-development operations in West Philadelphia in a move expected to create nearly 500 high-paying jobs.
The gene therapy company spun out of Children’s Hospital of Philadelphia is getting a $2 million Department of Community and Economic Development grant and a $7.5 million grant from the Redevelopment Assistance Capital Program to support the project.
Spark’s new site will be located on Market Street in Brandywine Realty Trust’s $3 billion Schuylkill Yards development project with Drexel University. The company’s existing offices are at 3737 Market Street.
“This expansion is proof of our continued commitment to research, development, and innovation in West Philadelphia and of our determination to offer new genetic treatments for people living with genetic diseases,” said Co-founder and CEO Jeffrey D. Marrazzo.
Read more at bizjournals.com
Oct10Wed
Almac Group Invests to Expand its Existing North Carolina Facility
Continued expansion and investment to support increasing client demand
| Souderton, PA, US, 10 October 2018 – Almac Group, the global contract pharmaceutical development and manufacturing organisation, today announced the completion of an investment in its Durham, North Carolina Clinical Services’ and Diagnostic Services’ capabilities with the opening of a 24,000 sq. ft. building. |
Oct10Wed
Teleflex Acquires Essential Medical
Acquisition expands presence in structural heart and endovascular aneurysm repair markets by adding unique large bore closure system
October 04, 2018 05:00 PM Eastern Daylight Time
WAYNE, Pa.–(BUSINESS WIRE)–Teleflex Incorporated (NYSE: TFX) today announced that it has acquired Essential Medical, Inc. Based in Exton, PA, Essential Medical is a privately-held medical device company that has developed and commercialized the CE Marked MANTA™ Vascular Closure Device specifically designed for closure of large bore arteriotomies following procedures utilizing devices or sheaths ranging in size from 10F to 18F (with maximum outer diameters up to 25F). In its CE Mark study, the MANTA Device demonstrated rapid and reliable hemostasis with its resorbable collagen-based technology and complication rates that were non-inferior to surgical and suture-based closure methods.(1)
Oct09Tue
 Arran Chemical Company Completes Stage II of its Strategic Plan “ADAPT” Completion of multi-million Euro expansion of manufacturing capacity and deployment of next generation production technologies
|
|
| Athlone, Ireland, 09 October 2018 – as reported in October 2017, Irish based Arran Chemical Company, has responded to client demand for the provision of fine chemicals, pharmaceutical intermediates and advanced building blocks by implementation of its three stage ADAPT (Arran Deploys Advanced Production Technologies) strategy through a multi-million Euro investment. The investment is focused around increasing capacity, further application of its selectAZyme™ biocatalysis technology and implementation of flow chemistry. Arran is proud to announce the completion of Stage II of the strategy and the positive benefit to its global client base. |
2019 Governor’s Awards for Local Government Excellence: Do you have local government leaders in your community who demonstrate exceptional dedication to improving public services?
Click HERE to submit nominations.
